查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726328

美国生物製药契约製造市场：市场规模、份额、趋势分析（按原材料、服务、产品、类型、业务规模和治疗领域）、细分市场预测（2025-2030 年）

U.S. Biopharmaceuticals Contract Manufacturing Market Size, Share, & Trends Analysis Report By Source, By Service, By Products, By Type, By Scale Of Operation, By Therapeutic Area, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国生物製药契约製造市场的成长与趋势：

根据 Grand View Research, Inc. 的一份新报告，美国生物製药契约製造市场预计到 2030 年将达到 195.4 亿美元，2025 年至 2030 年期间的复合年增长率为 10.6%。

由于对采用创新治疗方法复杂疾病的生技药品和生物相似药的需求不断增加，美国生物製药契约製造市场正在成长。一次性系统和连续加工等製造技术的进步正在提高生产效率和扩充性。这些因素使契约製造製造商能够满足对具有成本效益的高品质生物製药日益增长的需求，从而推动市场成长并激发行业创新。

由于注重成本效益生产和合约製造业务(CMO) 的扩张，市场正在蓬勃发展。外包製造可以让公司降低营运成本并将资源分配到创新上。 CMO 提供可扩展的解决方案、先进的技术和专业知识，以确保高效生产。 CMO 的成长将使生物製药公司能够满足对生技药品和生物相似药日益增长的需求，促进市场扩张并激发行业创新。

慢性病的增加推动了对先进生物药物（包括生技药品和生物相似药）的需求，以应对复杂的健康挑战。同时，一次性系统和连续生产等生物加工领域的创新正在彻底改变生产效率和可扩展性。这些进步使契约製造製造商能够满足对高品质、高性价比治疗方法日益增长的需求，为美国生物製药行业的成长和发展做出了重大贡献。

美国生物製药契约製造市场：概述

  • 基于原料，哺乳动物部分在製造单株抗体和重组蛋白等生技药品方面发挥着至关重要的作用，预计到 2024 年将占据最大份额。
  • 按服务划分，流程开发部门在 2024 年占据市场最大收入份额，达 34.8%。这是因为它在优化生产效率和确保法规遵循方面发挥着至关重要的作用。
  • 由于生物製药製造对严格品质保证和法规遵从性的需求日益增加，预计分析和品管(QC) 研究领域在预测期内将以最快的复合年增长率成长。
  • 根据产品，由于对单株抗体、细胞和基因疗法以及生物相似药等先进疗法的需求不断增加，生技药品领域预计将在 2024 年占据最大份额。
  • 预计生物相似药领域将成为 2025 年至 2030 年间成长最快的领域。

目录

第一章 分析方法与范围

第二章执行摘要

第三章美国生物製药契约製造市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL分析

第四章美国生物製药契约製造市场：原料业务分析

  • 原料市场占有率（2024 年及 2030 年）
  • 按成分分類的仪表板
  • 按原料分類的市场规模预测与趋势分析（2018-2030）
  • 哺乳动物
  • 非哺乳动物

第五章美国生物製药契约製造市场：按服务分類的业务分析

  • 各服务市场占有率（2024 年及 2030 年）
  • 特定于服务的仪表板
  • 市场规模预测及服务趋势分析（2018-2030）
  • 製程开发
  • 填充和整理工作
  • 分析和品管（QC）调查
  • 包装和标籤
  • 其他的

第六章美国生物製药契约製造市场：按产品分類的业务分析

  • 各产品市场占有率（2024 年及 2030 年）
  • 产品仪表板
  • 市场规模预测及产品趋势分析（2018-2030）
  • 生技药品
  • 生物相似药

第七章美国生物製药契约製造市场：按类型分類的业务分析

  • 按类型分類的市场占有率（2024 年和 2030 年）
  • 按类型分類的仪表板
  • 按类型分類的市场规模预测和趋势分析（2018-2030）
  • 原料药
  • 成品药品

第八章美国生物製药契约製造市场：按业务规模进行的业务分析

  • 按企业规模分類的市场占有率（2024 年和 2030 年）
  • 按业务规模分類的仪表板
  • 按业务规模分類的市场规模预测和趋势分析（2018-2030 年）
  • 临床
  • 实际的

第九章美国生物製药契约製造市场：按治疗领域分類的业务分析

  • 按治疗领域分類的市场占有率（2024 年和 2030 年）
  • 治疗区域仪表板
  • 依治疗领域分類的市场规模预测及趋势分析（2018-2030）
  • 瘤
  • 自体免疫疾病
  • 感染疾病
  • 心血管疾病
  • 代谢疾病
  • 神经病学
  • 其他的

第十章 竞争格局

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Lonza
    • WuXi Biologics
    • FUJIFILM Diosynth Biotechnologies
    • Boehringer Ingelheim International GmbH
    • Thermo Fisher Scientific Inc.
    • Samsung Biologics
    • AGC Biologics
    • Catalent, Inc
    • Rentschler Biopharma SE
    • Eurofins Scientific
Product Code: GVR-4-68040-223-7

U.S. Biopharmaceuticals Contract Manufacturing Market Growth & Trends:

The U.S. biopharmaceuticals contract manufacturing market is anticipated to reach USD 19.54 billion by 2030 and expand at a CAGR of 10.6% from 2025 to 2030, according to a new report by Grand View Research, Inc.The U.S. biopharmaceuticals contract manufacturing market is growing due to the rising demand for biologics and biosimilars, which address complex diseases with innovative therapies. Advancements in manufacturing technologies, such as single-use systems and continuous processing, enhance production efficiency and scalability. These factors enable contract manufacturers to meet the rising need for cost-effective and high-quality biopharmaceuticals, driving market growth and fostering innovation in the industry.

The market thrives due to a focus on cost-effective production and the expansion of Contract Manufacturing Organizations (CMOs). By outsourcing manufacturing, companies reduce operational costs and allocate resources for innovation. CMOs provide scalable solutions, advanced technologies, and specialized expertise, ensuring efficient production. Their growth enables biopharma companies to meet the rising demand for biologics and biosimilars, driving market expansion and fostering innovation in industry.

The growing prevalence of chronic diseases fuels the demand for advanced biopharmaceuticals, including biologics and biosimilars, to address complex health challenges. Simultaneously, technological innovations in bioprocessing, such as single-use systems and continuous manufacturing, are revolutionizing production efficiency and scalability. These advancements empower contract manufacturers to meet the rising need for high-quality, cost-effective therapies and contribute significantly to the growth and evolution of the biopharmaceutical industry in the U.S.

U.S. Biopharmaceuticals Contract Manufacturing Market Report Highlights:

  • By source, the mammalian segment held the largest share in 2024, owing toits critical role in producing biologics like monoclonal antibodies and recombinant proteins.
  • By service, the process development segment led the market with the largest revenue share of 34.8% in 2024, driven byits pivotal role in optimizing production efficiency and ensuring regulatory compliance.
  • Theanalytical & QC studies segment is set to grow at the fastest CAGR over the forecast period, fueled bythe increasing need for stringent quality assurance and regulatory compliance in biopharmaceutical production.
  • By products, the biologics segment dominated the market with the largest share in 2024 due toincreasing demand for advanced therapies like monoclonal antibodies, cell and gene therapies, and biosimilars.
  • The biosimilars segment is projected to be the fastest-growing segment from 2025 to 2030, attributed to increasing demand for cost-effective alternatives to biologics.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Source
    • 1.2.2. Service
    • 1.2.3. Products
    • 1.2.4. Type
    • 1.2.5. Scale of Operation
    • 1.2.6. Therapeutic Area
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Biopharmaceuticals Contract Manufacturing Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. U.S. Biopharmaceuticals Contract Manufacturing Market: Source Business Analysis

  • 4.1. Source Market Share, 2024 & 2030
  • 4.2. Source Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, By Source, 2018 to 2030 (USD Million)
  • 4.4. Mammalian
    • 4.4.1. Mammalian Market, 2018 - 2030 (USD Million)
  • 4.5. Non-mammalian
    • 4.5.1. Non-mammalian Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Biopharmaceuticals Contract Manufacturing Market: Service Business Analysis

  • 5.1. Service Market Share, 2024 & 2030
  • 5.2. Service Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, By Service, 2018 to 2030 (USD Million)
  • 5.4. Process Development
    • 5.4.1. Process Development Market, 2018 - 2030 (USD Million)
    • 5.4.2. Downstream
      • 5.4.2.1. Downstream Market, 2018 - 2030 (USD Million)
    • 5.4.3. Upstream
      • 5.4.3.1. Upstream Market, 2018 - 2030 (USD Million)
  • 5.5. Fill & Finish Operations
    • 5.5.1. Fill & Finish Operations Market, 2018 - 2030 (USD Million)
  • 5.6. Analytical & QC Studies
    • 5.6.1. Analytical & QC Studies Market, 2018 - 2030 (USD Million)
  • 5.7. Packaging & Labelling
    • 5.7.1. Packaging & Labelling Market, 2018 - 2030 (USD Million)
  • 5.8. Others
    • 5.8.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Biopharmaceuticals Contract Manufacturing Market: Products Business Analysis

  • 6.1. Products Market Share, 2024 & 2030
  • 6.2. Products Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, By Products, 2018 to 2030 (USD Million)
  • 6.4. Biologics
    • 6.4.1. Biologics Market, 2018 - 2030 (USD Million)
    • 6.4.2. Monoclonal Antibodies (mAbs)
      • 6.4.2.1. Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
    • 6.4.3. Recombinant Proteins
      • 6.4.3.1. Recombinant Proteins Market, 2018 - 2030 (USD Million)
    • 6.4.4. Vaccines
      • 6.4.4.1. Vaccines Market, 2018 - 2030 (USD Million)
    • 6.4.5. Antisense, RNAi, & Molecular Therapy
      • 6.4.5.1. Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
    • 6.4.6. Others
      • 6.4.6.1. Others Market, 2018 - 2030 (USD Million)
  • 6.5. Biosimilars
    • 6.5.1. Biosimilars Market, 2018 - 2030 (USD Million)

Chapter 7. U.S. Biopharmaceuticals Contract Manufacturing Market: Type Business Analysis

  • 7.1. Type Market Share, 2024 & 2030
  • 7.2. Type Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, By Type, 2018 to 2030 (USD Million)
  • 7.4. Drug Substance
    • 7.4.1. Drug Substance Market, 2018 - 2030 (USD Million)
  • 7.5. Finished Drug Product
    • 7.5.1. Finished Drug Product Market, 2018 - 2030 (USD Million)

Chapter 8. U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Business Analysis

  • 8.1. Scale of Operation Market Share, 2024 & 2030
  • 8.2. Scale of Operation Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, By Scale of Operation, 2018 to 2030 (USD Million)
  • 8.4. Clinical
    • 8.4.1. Clinical Market, 2018 - 2030 (USD Million)
  • 8.5. Commercial
    • 8.5.1. Commercial Market, 2018 - 2030 (USD Million)

Chapter 9. U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Business Analysis

  • 9.1. Therapeutic Area Market Share, 2024 & 2030
  • 9.2. Therapeutic Area Segment Dashboard
  • 9.3. Market Size & Forecasts and Trend Analysis, By Therapeutic Area, 2018 to 2030 (USD Million)
  • 9.4. Oncology
    • 9.4.1. Oncology Market, 2018 - 2030 (USD Million)
  • 9.5. Autoimmune Diseases
    • 9.5.1. Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • 9.6. Infectious Diseases
    • 9.6.1. Infectious Diseases Market, 2018 - 2030 (USD Million)
  • 9.7. Cardiovascular Diseases
    • 9.7.1. Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • 9.8. Metabolic Diseases
    • 9.8.1. Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • 9.9. Neurology
    • 9.9.1. Neurology Market, 2018 - 2030 (USD Million)
  • 9.10. Others
    • 9.10.1. Others Market, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. Lonza
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Product Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. WuXi Biologics
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Product Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. FUJIFILM Diosynth Biotechnologies
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Product Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Boehringer Ingelheim International GmbH
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Product Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Thermo Fisher Scientific Inc.
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Product Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Samsung Biologics
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Product Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. AGC Biologics
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Product Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. Catalent, Inc
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Product Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Rentschler Biopharma SE
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Product Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Eurofins Scientific
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Product Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Biopharmaceuticals Contract Manufacturing Market, By Source, 2018 - 2030 (USD Million)
  • Table 4 U.S. Biopharmaceuticals Contract Manufacturing Market, By Service, 2018 - 2030 (USD Million)
  • Table 5 U.S. Biopharmaceuticals Contract Manufacturing Market, By Products, 2018 - 2030 (USD Million)
  • Table 6 U.S. Biopharmaceuticals Contract Manufacturing Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 U.S. Biopharmaceuticals Contract Manufacturing Market, By Scale of Operation, 2018 - 2030 (USD Million)
  • Table 8 U.S. Biopharmaceuticals Contract Manufacturing Market, By Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 U.S. Biopharmaceuticals Contract Manufacturing Market Segmentation
  • Fig. 2 Market Research Process
  • Fig. 3 Data Triangulation Techniques
  • Fig. 4 Primary Research Pattern
  • Fig. 5 Market Research Approaches
  • Fig. 6 Value-Chain-Based Sizing & Forecasting
  • Fig. 7 Market Formulation & Validation
  • Fig. 8 Market Snapshot
  • Fig. 9 Service and Technique Outlook (USD Million)
  • Fig. 10 Competitive Landscape
  • Fig. 11 U.S. Biopharmaceuticals Contract Manufacturing Market Dynamics
  • Fig. 12 U.S. Biopharmaceuticals Contract Manufacturing Market: Porter's Five Forces analysis
  • Fig. 13 U.S. Biopharmaceuticals Contract Manufacturing Market: PESTLE Analysis
  • Fig. 14 U.S. Biopharmaceuticals Contract Manufacturing Market: Source Segment Dashboard
  • Fig. 15 U.S. Biopharmaceuticals Contract Manufacturing Market: Source Market Share Analysis, 2024 & 2030
  • Fig. 16 Mammalian Market, 2018 - 2030 (USD Million)
  • Fig. 17 Mammalian Market, 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Biopharmaceuticals Contract Manufacturing Market: Service Segment Dashboard
  • Fig. 19 U.S. Biopharmaceuticals Contract Manufacturing Market: Service Market Share Analysis, 2024 & 2030
  • Fig. 20 Process Development Market, 2018 - 2030 (USD Million)
  • Fig. 21 Downstream Market, 2018 - 2030 (USD Million)
  • Fig. 22 Upstream Market, 2018 - 2030 (USD Million)
  • Fig. 23 Fill & Finish Operations Market, 2018 - 2030 (USD Million)
  • Fig. 24 Analytical & QC Studies Market, 2018 - 2030 (USD Million)
  • Fig. 25 Packaging & Labelling Market, 2018 - 2030 (USD Million)
  • Fig. 26 Others Market, 2018 - 2030 (USD Million)
  • Fig. 27 U.S. Biopharmaceuticals Contract Manufacturing Market: Products Segment Dashboard
  • Fig. 28 U.S. Biopharmaceuticals Contract Manufacturing Market: Products Market Share Analysis, 2024 & 2030
  • Fig. 29 Biologics Market, 2018 - 2030 (USD Million)
  • Fig. 30 Monoclonal Antibodies (mAbs) Market, 2018 - 2030 (USD Million)
  • Fig. 31 Recombinant Proteins Market, 2018 - 2030 (USD Million)
  • Fig. 32 Vaccines Market, 2018 - 2030 (USD Million)
  • Fig. 33 Antisense, RNAi, & Molecular Therapy Market, 2018 - 2030 (USD Million)
  • Fig. 34 Others Market, 2018 - 2030 (USD Million)
  • Fig. 35 Biosimilars Market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. Biopharmaceuticals Contract Manufacturing Market: Type Segment Dashboard
  • Fig. 37 U.S. Biopharmaceuticals Contract Manufacturing Market: Type Market Share Analysis, 2024 & 2030
  • Fig. 38 Drug Substance Market, 2018 - 2030 (USD Million)
  • Fig. 39 Finished Drug Product Market, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Segment Dashboard
  • Fig. 41 U.S. Biopharmaceuticals Contract Manufacturing Market: Scale of Operation Market Share Analysis, 2024 & 2030
  • Fig. 42 Clinical Market, 2018 - 2030 (USD Million)
  • Fig. 43 Commercial Market, 2018 - 2030 (USD Million)
  • Fig. 44 U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Segment Dashboard
  • Fig. 45 U.S. Biopharmaceuticals Contract Manufacturing Market: Therapeutic Area Market Share Analysis, 2024 & 2030
  • Fig. 46 Oncology Market, 2018 - 2030 (USD Million)
  • Fig. 47 Autoimmune Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 48 Infectious Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 49 Cardiovascular Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 50 Metabolic Diseases Market, 2018 - 2030 (USD Million)
  • Fig. 51 Neurology Market, 2018 - 2030 (USD Million)
  • Fig. 52 Others Market, 2018 - 2030 (USD Million)
  • Fig. 53 Company Categorization
  • Fig. 54 Company Market Position Analysis
  • Fig. 55 Strategic Framework